CNTX

#4405
Context Therapeutics Inc. - Common Stock
0.3 8 USD
-0.10%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.38
0.38
Jahresspanne
0.38
3.62
Tagesänderung
-9.52%
Monatliche Änderung
-38.71%
6 month change
-82.73%
Jahresänderung
-55.29%
Vorheriger Schlusskurs
0.4 2
Open
0.3 8
Tief
0.3 8
Hoch
0.3 8
Volumen
20
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Context Therapeutics Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Context Therapeutics Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Context Therapeutics Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Context Therapeutics Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Context Therapeutics Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Context Therapeutics Inc. current report, Q1 FY2026
8-K

Context Therapeutics Inc. current report, Q1 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Context Therapeutics Inc. on February 24, 2026. The filing addresses a legal settlement regarding a stockholder class action complaint filed on February 4, 2026, by the Vladimir Gusinsky Revocable Trust against the Company and its directors.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and legal proceedings rather than financial performance.

Material Changes and Legal Proceedings

  • Stipulated Judgment: A stipulation and proposed consent judgment was filed with the Court of Chancery of the State of Delaware to resolve the stockholder class action.
  • Charter Provisions: The parties seek a court determination that two provisions in the Company's Amended and Restated Certificate of Incorporation are invalid and unenforceable:
    • Article V, Section 2: Directors serving for a three-year term.
    • Article VI, Section 1: Directors removable only for cause.
  • Dismissal: The Action is to be dismissed with prejudice upon court approval.
  • Corporate Action: If approved, the Company will file a Certificate of Correction with the Delaware Secretary of State to reflect the invalidation of these provisions.

Outlook, Management Commentary, and Risks

  • 2026 Annual Meeting: The meeting is scheduled for June 24, 2026, with a record date of April 27, 2026.
  • Director Elections: The Company intends to propose the election of director nominees to a one-year term until their successors are elected or qualified.
  • Stockholder Proposals:
    • Deadline for proposals under Bylaws: March 14, 2026, by 5:00 p.m. EDT.
    • Deadline for universal proxy rule compliance (Rule 14a-19): April 13, 2026.
  • Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks regarding the Court's approval of the Stipulated Judgment and the Company's ability to execute its plans.

Investor Verification Checklist

  • Verify the Court of Chancery's final approval of the Stipulated Judgment.
  • Confirm the filing of the Certificate of Correction with the Delaware Secretary of State.
  • Monitor the agenda for the June 24, 2026, Annual Meeting for any stockholder proposals or director nominations.
  • Review the Company's most recent 10-K or 10-Q for financial data not included in this 8-K.

Nachrichten